@ahleesahhh's peptide mixing tutorial: is the math right?
Quick answer
The video demonstrates reconstitution of retatrutide, an investigational tri-agonist peptide targeting GLP-1, GIP, and glucagon receptors, using a 1mg per 10 units on a 100-unit insulin syringe convention. Retatrutide has shown significant weight reduction in Phase 2 trials (Jastreboff et al., 2023, NEJM) but carries no approved dosing protocol, and self-administration guidance from social media bypasses the clinical monitoring these trials required. Compounded retatrutide sourced outside a regulated telehealth pathway has no verified potency, sterility, or safety data.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @ahleesahhh's peptide mixing tutorial: is the math right?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@ahleesahhh's peptide mixing tutorial: is the math right? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@ahleesahhh's peptide mixing tutorial: is the math right?" from Thatgirlahleesah🦋. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video demonstrates reconstitution of retatrutide, an investigational tri-agonist peptide targeting GLP-1, GIP, and glucagon receptors, using a 1mg per 10 units on a 100-unit insulin syringe convention.
The reason this review is not generic is the canonical claim label "peptides a little video to help anyone out with their maths reconsti." The review points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video demonstrates reconstitution of retatrutide, an investigational tri-agonist peptide targeting GLP-1, GIP, and glucagon receptors, using a 1mg per 10 units on a 100-unit insulin syringe convention.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video demonstrates reconstitution of retatrutide, an investigational tri-agonist peptide targeting GLP-1, GIP, and glucagon receptors, using a 1mg per 10 units on a 100-unit insulin syringe convention. Retatrutide has shown significant weight reduction in Phase 2 trials (Jastreboff et al., 2023, NEJM) but carries no approved dosing protocol, and self-administration guidance from social media bypasses the clinical monitoring these trials required. Compounded retatrutide sourced outside a regulated telehealth pathway has no verified potency, sterility, or safety data.
- The 1mg per 10 units rule on a 100-unit syringe is arithmetically correct when 10mg peptide is dissolved in exactly 1ml bacteriostatic water, but it is a convention not a regulated clinical standard.
- Retatrutide is an investigational GLP-1/GIP/glucagon tri-agonist with no FDA or TGA approval. Phase 2 data published in NEJM (Jastreboff et al., 2023) showed up to 24.2% weight loss but under monitored trial conditions.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The 1mg per 10 units rule on a 100-unit syringe is arithmetically correct when 10mg peptide is dissolved in exactly 1ml bacteriostatic water, but it is a convention not a regulated clinical standard.
- Retatrutide is an investigational GLP-1/GIP/glucagon tri-agonist with no FDA or TGA approval. Phase 2 data published in NEJM (Jastreboff et al., 2023) showed up to 24.2% weight loss but under monitored trial conditions.
- Bacteriostatic water preserved with 0.9% benzyl alcohol typically maintains a reconstituted peptide for up to 28 days when refrigerated at 2-8 degrees Celsius. The video does not mention this storage window.
- Gentle swirling is the correct reconstitution technique. Shaking can cause peptide aggregation and degradation, consistent with stability data in Manning et al. (2019, Journal of Pharmaceutical Sciences).
- The video correctly distinguishes total peptide mass from post-reconstitution concentration, which is a meaningful educational point that reduces dosing errors.
- No dose calculator replaces clinical oversight. Retatrutide and other GLP-1 class compounds carry risks including nausea, vomiting, elevated heart rate, and potential pancreatitis that require prescriber monitoring.
- Compounded peptides sourced outside a regulated pharmacy or telehealth pathway have no verified potency or sterility. The math only works if the labeled peptide mass is accurate, which cannot be assumed from unregulated suppliers.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @ahleesahhh actually say?
The creator walked through how to reconstitute a lyophilized peptide, specifically using retatrutide as the example. The core advice: dissolve 10mg of peptide in exactly 1ml of bacteriostatic water. This produces, in her words, math that is "a whole lot easier" because on a 100-unit insulin syringe, each 10 units equals 1mg of peptide. She then demonstrated dose scaling, showing that 1mg requires drawing 10 units, 2mg requires 20 units, and 5mg requires 50 units. She also noted that some people use 3ml per vial but said this makes the calculation "a bit messy."
She was careful to distinguish between total peptide mass and dosing strength, saying "10mg is not the strength. It is the total amount of product in this vial." That distinction matters, and she made it clearly.
Does the science back this up?
The math itself is correct. The chemistry of reconstitution supports this approach, with some important caveats she did not address. Bacteriostatic water is the appropriate diluent for most research-grade lyophilized peptides, and the 1ml per 10mg ratio is a widely used convention. The linear scaling she demonstrated is arithmetically sound for a homogeneous solution.
What the science also tells us is that reconstitution technique matters beyond just ratios. A 2019 review by Manning et al. in the Journal of Pharmaceutical Sciences documented that agitation method, temperature, and pH of the diluent all affect peptide stability after reconstitution. Swirling gently, as she recommends rather than shaking, is consistent with standard handling guidance for fragile peptide bonds. However, no peer-reviewed literature specifically validates the 1ml per 10mg ratio as a clinical standard. It is a practical convention, not a regulated protocol.
What did they get right, and what's missing?
Credit where it is due: the instruction to add water at an angle and swirl rather than shake is correct. Vigorous shaking can introduce air bubbles and potentially denature peptides. The distinction she draws between total peptide mass and concentration is genuinely useful and frequently misunderstood by newcomers.
The gaps are significant though. She did not mention storage conditions after reconstitution. Most lyophilized peptides, once reconstituted in bacteriostatic water, should be refrigerated at 2-8 degrees Celsius and used within a defined window, typically 28 days according to standard compounding guidance. She also did not address the fact that retatrutide specifically is an investigational GLP-1/GIP/glucagon receptor tri-agonist with no approved dosing protocol outside clinical trials. Presenting dose escalation from 1mg to 5mg as routine weekly math glosses over the fact that this compound has only completed Phase 2 trials. Lilly's 2023 Phase 2 data published in the New England Journal of Medicine used doses up to 12mg weekly, but under monitored clinical conditions, not self-injection at home based on a TikTok calculator.
What should you actually know?
The reconstitution math tutorial is largely accurate as a mechanical exercise. But math accuracy does not equal safety. Several things this video does not tell you matter more than unit conversions.
- Bacteriostatic water contains 0.9% benzyl alcohol as a preservative. People with benzyl alcohol sensitivity should not use it.
- Reconstituted peptides are not sterile indefinitely. The 28-day refrigerated window for bacteriostatic water preparations is a compounding standard, not a conservative estimate.
- Retatrutide is not approved by the FDA, TGA, or any other major regulatory body as of 2024. It is available only through compounding pharmacies or gray-market research chemical suppliers, and quality varies considerably.
- Dosing decisions for any GLP-1 class compound, investigational or otherwise, should involve a prescribing clinician who can monitor for gastrointestinal side effects, heart rate changes, and pancreatitis risk.
The calculator she references may be useful for arithmetic, but no app accounts for individual pharmacokinetics, body weight, renal function, or drug interactions. A formula does not replace a prescriber.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Thatgirlahleesah🦋 · TikTok creator
142.3K views on this video
A little video to help anyone out with their maths #reconstituting #howtomixpeptides
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the evidence say about the 1mg per 10 units rule on a 100-unit syringe?
The 1mg per 10 units rule on a 100-unit syringe is arithmetically correct when 10mg peptide is dissolved in exactly 1ml bacteriostatic water, but it is a convention not a regulated clinical standard.
What does the evidence say about retatrutide?
Retatrutide is an investigational GLP-1/GIP/glucagon tri-agonist with no FDA or TGA approval. Phase 2 data published in NEJM (Jastreboff et al., 2023) showed up to 24.2% weight loss but under monitored trial conditions.
What does the evidence say about bacteriostatic water preserved with 0.9% benzyl alcohol typically maintains a?
Bacteriostatic water preserved with 0.9% benzyl alcohol typically maintains a reconstituted peptide for up to 28 days when refrigerated at 2-8 degrees Celsius. The video does not mention this storage window.
What does the evidence say about gentle swirling?
Gentle swirling is the correct reconstitution technique. Shaking can cause peptide aggregation and degradation, consistent with stability data in Manning et al. (2019, Journal of Pharmaceutical Sciences).
What does the evidence say about the video correctly distinguishes total peptide mass from post-reconstitution concentration?
The video correctly distinguishes total peptide mass from post-reconstitution concentration, which is a meaningful educational point that reduces dosing errors.
What does the evidence say about no dose calculator replaces clinical oversight. retatrutide?
No dose calculator replaces clinical oversight. Retatrutide and other GLP-1 class compounds carry risks including nausea, vomiting, elevated heart rate, and potential pancreatitis that require prescriber monitoring.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Thatgirlahleesah🦋, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.